Posted by Michael Wonder on 07 Mar 2025
Neurotech’s Encelto (revakinagene taroretcel-lwey) approved by the FDA for the treatment of macular telangiectasia type 2
6 March 2025 - Encelto is the first and only FDA approved treatment for macular telangiectasia type 2.
Neurotech Pharmaceuticals announced that the US FDA has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2.
